European Journal of Clinical Pharmacology

, Volume 41, Issue 5, pp 429–434 | Cite as

Pharmacodynamics of ticlopidine in man in relation to plasma and blood cell concentration

  • T. Di Perri
  • F. L. Pasini
  • C. Frigerio
  • P. Blardi
  • F. Centini
  • G. L. Messa
  • A. Ghezzi
  • L. Volpi
Originals

Summary

In 6 normal volunteers given single oral doses of 250, 500 and 1000 mg ticlopidine (T), the peak plasma level of unchanged drug was reached after about 2 h. There was no correlation between the plasma T level and its inhibitory effect on platelet function, expressed as % inhibition of ADP-induced aggregation. By means of HPLC and GC/MS significant concentrations of T were demonstrated in washed red cells, platelets and neutrophils, with a marked difference in the time course of the appearance of cell-associated drug. The time course of platelet-associated T very accurately fitted that of the antiaggregatory activity.

After subacute oral administration (250 mg b. d. for 7 days), the maximum effect on platelet function was observed after 3 to 4 days, when a significant concentration of platelet-associated T had been reached. The pharmacological effect persisted as long as drug was detectable in platelet.

An in vitro study strongly suggested that the antiaggregating effect was retained by treated washed platelets but not by treated plasma. It is suggested that the platelet compartment represents the pharmacological target of T via a specific uptake system.

Key words

Ticlopidine Platelet aggregation Anti-aggregating drugs Pharmacodynamics plasma levels intracellular drug adverse effects 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Pedersen AK, Fitzgerald GA (1985) The human pharmacology of platelet inhibition: pharmacokinetics relevant to drug action. Circulation 72: 1164–1176Google Scholar
  2. 2.
    Patrono C, Ciabattoni G, Patrignani P, et al. (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 1177–1184Google Scholar
  3. 3.
    White JG (1971) Platelet morphology. In: Johnson SA Ed. The circulating platelet. Academic Press, New York pp 45–121Google Scholar
  4. 4.
    Ashida S, Abiko Y (1979) Inhibition of platelet aggregation by a new agent, ticlopidine. Thromb Haemost 40: 542–550Google Scholar
  5. 5.
    Bruno JJ (1983) The mechanism of action of ticlopidine. Thromb Res [Suppl] 4: 59–67Google Scholar
  6. 6.
    Picard-Fraire C (1983) Ticopidine hydrochloride: relation between dose, kinetics, plasma concentration and effect on platelet function. Thromb Res [Suppl] 4: 119–128Google Scholar
  7. 7.
    Picard-Fraire C (1984) Pharmacokinetic and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function. Agents Actions 15 [Suppl]: 68–75Google Scholar
  8. 8.
    Saltiel E, Ward A (1987) Ticlopidine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 34: 222–262Google Scholar
  9. 9.
    Panak E, Maffrand JB, Picard-Fraire C, Vallee E, Blanchard J, Roncucci R (1983) Ticlopidine: a promise for the prevention and treatment of thrombosis and its complication. Haemostasis 13 [Suppl 1]: 1–54Google Scholar
  10. 10.
    Thebault JJ, Blatrix CE, Blanchard JF, Panak EA (1975) Effects of ticlopidine, a new platelet aggregation inhibitor in man. Clin Pharmacol Ther 18: 485–490Google Scholar
  11. 11.
    Born GVR (1962) Aggregation of blood platelet by adenosine diphosphate and its reversal. Nature 194: 927–929Google Scholar
  12. 12.
    Mustard JF, Perry DW, Ardle NG, Packham MA (1972) Preparation of suspension of washed platelet from humans. Br J Haematol 22: 193–204Google Scholar
  13. 13.
    Laghi Pasini F, Pasqui AL, Ceccatelli L, Capecchi PL, Orrico A, Di Perri T (1984) Heparin inhibition of polymorphonuclear leukocyte activation in vitro. A possible pharmacological approach to granulocyte-mediated vascular damage. Thromb Res 35: 527–537Google Scholar
  14. 14.
    Muir KT (1980) Non-linear least squares regression analysis in pharmacokinetics: application of a programmable calculator in model parameter estimation. Comput Biomed Res 13: 307–316Google Scholar
  15. 15.
    Aronson JK, Dengler HJ, Dettli L, Follath F (1988) Standardization of symbols in clinical pharmacology. Eur J Clin Pharmacol 35: 1–7Google Scholar
  16. 16.
    Tohgi H (1984) The effect of ticlopidine on TIA compared with aspirin: a double-blind, twelve-month follow-up study. Agents Actions [Suppl] 15: 279–282Google Scholar
  17. 17.
    Limet R, David JL, Magotteaux P, Larock MP, Rigo P (1987) Prevention of aorta-coronary bypass graft occlusion: beneficial effect of ticlopidine on early and late patency rates of venous coronary bypass grafts: a double-blind study. J Thor Cardiovasc Surg 94: 773–783Google Scholar
  18. 18.
    Feliste R, Delebassee B, Simon MF et al. (1987) Broad spectrum anti-platelet activity of ticlopidine and PCR 4099 involves the suppression of the effect of released ADP. Thromb Res 48: 403–415Google Scholar
  19. 19.
    Limet R, David JR, Rigo P (1984) Ticlopidine and coronary surgery. Agents Actions [Suppl] 15: 188–198Google Scholar
  20. 20.
    Hass WK, Easton D, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B (1989) A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 321: 501–507Google Scholar

Copyright information

© Springer-Verlag 1991

Authors and Affiliations

  • T. Di Perri
    • 1
    • 3
  • F. L. Pasini
    • 1
  • C. Frigerio
    • 1
  • P. Blardi
    • 1
  • F. Centini
    • 2
  • G. L. Messa
    • 1
  • A. Ghezzi
    • 1
  • L. Volpi
    • 1
  1. 1.Department of Internal MedicineUniversity of SineaSienaItaly
  2. 2.Department of Forensic Medicine School of MedicineUniversity of SienaSienaItaly
  3. 3.Istituto di Clinica Medica Generale e Terapia MedicaPoliclinico “Le Scotte”SienaItaly

Personalised recommendations